4-FMA Capsules – 130mg
€ 18,00 – € 265,00Price range: € 18,00 through € 265,00
4-FMA Capsules 130mg are described as capsule-format research preparations associated with 4-fluoromethamphetamine, a para-fluorinated derivative of methamphetamine.
The named compound belongs to the substituted amphetamine and phenethylamine families and contains a fluorine substituent at the para position of its aromatic ring.
The supplied source identifies individual capsules with a labeled analyte quantity, intended for controlled analytical and non-clinical laboratory research.
Relevant scientific contexts include chemical identity assessment, chromatographic characterization, structural comparison, and investigation of related substituted amphetamines.
The source reports CAS number 351-03-1, molecular formula C10H14FN, and molecular weight approximately 167.22 g/mol.
It also refers to third-party analytical verification, Certificate of Analysis documentation, batch tracking, and ISO-compliant manufacturing.
However, no actual batch-specific certificate, independent laboratory report, or manufacturing certification was supplied.
Ingredient purity, finished-capsule analyte content, content uniformity, capsule-shell composition, excipients, chemical form, stereochemical identity, and storage stability remain unverified.
The capsules are not established as certified reference materials or validated quantitative calibration standards.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
4-FMA Capsules 130mg – Fluoromethamphetamine Research Material
4-FMA Capsules 130mg – Product Overview
4-FMA Capsules 130mg is the supplied catalog designation for a capsule-format research preparation associated with 4-fluoromethamphetamine.
The named compound belongs to the substituted amphetamine family and is structurally related to methamphetamine.
Its molecular structure differs from methamphetamine through the presence of a fluorine substituent at the para position of the aromatic ring.
The supplied source presents the product as individual capsules intended for controlled analytical and non-clinical laboratory research.
Each finished capsule is described as having a labeled analyte quantity.
However, no actual finished-unit assay or content-uniformity report accompanied the information.
The labeled quantity therefore remains a source-provided specification rather than an independently verified analytical result.
The supplied scientific context includes chemical identification, chromatographic characterization, structural comparison, and investigation of related substituted amphetamines.
These research contexts should be distinguished from verified findings about the actual finished capsules.
No batch-specific analytical identity certificate, impurity profile, or validated assay result was provided.
The source also refers to independent analytical verification, batch identification, and Certificate of Analysis documentation.
These statements remain unverified without supporting records.
The finished preparation is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.
Chemical Identity & Classification
The supplied source identifies 4-FMA as 4-fluoromethamphetamine.
It is a para-fluorinated methamphetamine analog belonging to the substituted amphetamine family.
The fluorine substituent distinguishes the named compound from methamphetamine and related positional analogs.
The supplied chemical information includes:
- Common designation: 4-FMA
- Descriptive chemical name: 4-Fluoromethamphetamine
- Systematic chemical name: 1-(4-Fluorophenyl)-N-methylpropan-2-amine
- Reported CAS Registry Number: 351-03-1
- Reported molecular formula: C10H14FN
- Calculated molecular weight from reported formula: Approximately 167.22 g/mol
- Chemical classification: Fluorinated substituted amphetamine
- Reported presentation: Capsules
- Labeled analyte amount: Specified per finished capsule
- Intended designation: Research Use Only
The reported molecular formula and calculated molecular weight are internally consistent for the neutral compound.
However, their assignment to the actual product batch has not been independently verified.
The source does not identify the exact stereochemical composition or establish whether the material is present as a free base or a salt.
These distinctions matter because substituted amphetamines can exhibit stereochemical variation and because a salt form has a different molecular formula and molecular weight from the neutral compound.
The molecular structure of the named compound does not establish the composition of the finished capsule preparation.
Additional excipients or capsule-shell components may be present, but the source does not identify them.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected database entry corresponds to the actual molecular structure, stereochemistry, and chemical form being examined.
Chemical & Physical Characteristics
The supplied source describes the product as capsules.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
A capsule is a finished preparation containing the named analyte together with any additional formulation components used in manufacture.
The characteristics of the complete preparation therefore differ from those of the isolated chemical compound.
The source does not identify the capsule-shell material, dimensions, total unit mass, fill composition, excipients, or manufacturing method.
The named compound contains a para-fluorinated aromatic group within the methamphetamine molecular framework.
This structural feature distinguishes 4-FMA from methamphetamine and from related positional fluorinated analogs.
The source does not provide experimentally verified solubility measurements or product-specific solvent compatibility records.
It also does not supply a capsule-dissolution study or analytical recovery assessment.
The absence of these records prevents any definitive claim about extraction performance, dissolution behavior, or analytical recovery from the finished capsules.
The source does not establish the distribution of analyte within the capsule contents.
Consequently, the properties of the isolated compound should not be assumed to describe the complete finished unit.
Purity & Analytical Verification
The supplied source claims ingredient purity of at least 98% and refers to third-party verification.
However, no actual batch-specific Certificate of Analysis or independent laboratory report accompanied that statement.
The reported purity therefore remains a supplier-provided claim rather than an independently verified result.
The source refers to HPLC, GC-MS, NMR spectroscopy, and LC-MS as analytical techniques relevant to chemical characterization.
No chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory certificate was supplied.
Accordingly, no specific purity result can be confirmed for the actual product batch.
For 4-FMA Capsules 130mg, the chemical purity of the named ingredient and the actual analyte quantity in each finished unit are separate analytical characteristics.
An ingredient-purity result does not independently establish finished-unit content or content uniformity.
The source also does not establish whether any claimed purity measurement applies to isolated bulk material or the complete finished preparation.
The material is described in reference-oriented research terms.
However, no certified reference-material documentation, assigned measurement value, uncertainty statement, or metrological traceability record was supplied.
The finished capsules should therefore not be represented as certified quantitative reference standards.
Any definitive analytical claims require actual supporting batch records.
Quality Control & Batch Integrity
The supplied source refers to third-party testing, batch identification, full documentation, and ISO-compliant production conditions.
These statements describe claimed quality-assurance practices.
No actual certificate, independent testing report, manufacturing audit, ISO certificate, or batch-specific quality-control record accompanied the information.
They therefore remain unverified supplier claims.
For reproducible analytical documentation, relevant records may include verified chemical identifiers, confirmed stereochemical composition where available, batch number, analytical findings, receipt date, and available storage history.
For 4-FMA Capsules 130mg, the identity and purity of the named compound should be distinguished from the composition and consistency of the finished units.
The supplied information does not establish independently verified analyte content, capsule-shell composition, excipients, or content uniformity.
The source also does not provide evidence that every finished capsule meets a particular quantitative specification.
The Research Use Only designation describes intended positioning but does not independently demonstrate manufacturing quality or analytical traceability.
Claims concerning batch consistency, independent testing, ISO compliance, and validated analytical performance should be supported by actual records.
Safety, Handling & Laboratory Precautions
4-FMA is a synthetic substituted amphetamine associated with stimulant-class pharmacological activity and potential toxicological uncertainty.
The supplied source does not provide a complete product-specific toxicological assessment.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The capsule presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical form, ingredient purity, capsule composition, and finished-unit content have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes discreet packaging, batch-aware handling, tracking, and professional shipment arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was provided.
The source recommends storage in a cool, dry environment protected from light.
It also suggests refrigeration at approximately 2–8°C.
No validated product-specific stability study was supplied to establish that temperature range as a verified requirement or to support a particular shelf life.
For 4-FMA Capsules 130mg, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The labeled analyte quantity should be recorded as a source-provided specification unless independently verified.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
The supplied scientific context places 4-FMA within analytical research involving substituted amphetamine chemical identity, aromatic fluorination, and comparative structural characterization.
The para-fluoro substituent provides a distinguishing structural feature relevant to chemical analysis.
The source also describes interest in chromatographic profiling, forensic analytical characterization, and investigation of related stimulant-class compounds.
However, no product-specific analytical validation, transporter-binding dataset, or stability study was supplied for the actual capsules.
The Raw Lab Chems catalog identifies 4-FMA Capsules as the product listing discussed here.
For related chemical-family and presentation context, the supplied catalog also includes 4-FMA Pellets and 3-FPM Pellets.
The first related listing refers to the same named compound in a different finished preparation.
The second refers to a distinct fluorinated stimulant-class compound.
4-FMA and 3-FPM should not be treated as chemically identical or analytically interchangeable.
The supplied information does not establish equivalent chemical purity, analyte content, excipient composition, or content uniformity across these preparations.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes professional packaging, international shipping, tracking, and secure handling arrangements.
No current inventory record, confirmed pack-size listing, carrier agreement, shipment authorization, or verified delivery information was supplied.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
4-FMA may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
4-FMA is a synthetic substituted amphetamine whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (capsules) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.